Entero Therapeutics, Inc.
ENTO
$0.55
$0.065713.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -57.91% | 37.06% | 60.16% | 59.82% | 61.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.71% | -0.95% | 32.63% | 226.89% | 182.77% |
| Operating Income | 64.71% | 0.95% | -32.63% | -226.89% | -182.77% |
| Income Before Tax | 64.14% | 1.11% | -18.15% | -155.45% | -129.50% |
| Income Tax Expenses | 128.64% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -274.38% | 1.11% | 49.48% | -20.44% | 34.27% |
| Earnings from Discontinued Operations | -1,227.23% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -304.22% | -14.34% | 36.72% | -37.18% | 32.15% |
| EBIT | 64.71% | 0.95% | -32.63% | -226.89% | -182.77% |
| EBITDA | 64.68% | 0.86% | -32.51% | -227.43% | -183.43% |
| EPS Basic | 83.82% | 94.87% | 94.24% | -105.80% | -116.32% |
| Normalized Basic EPS | 97.11% | 92.41% | 87.69% | -107.17% | -117.10% |
| EPS Diluted | 84.68% | 91.77% | 91.86% | -106.99% | -117.55% |
| Normalized Diluted EPS | 96.86% | 97.63% | 92.22% | -105.73% | -116.00% |
| Average Basic Shares Outstanding | 395.82% | 768.53% | 1,187.93% | 1,340.29% | 1,120.68% |
| Average Diluted Shares Outstanding | -4.68% | 1,688.01% | 2,936.83% | 4,858.54% | 6,244.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |